• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Provectus Biopharmaceuticals Inc (OP:PVCT)

0.0530 +0.0007 (+1.34%)
Delayed Quote Updated: 2:23 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 30,430
Open 0.0523
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0523
Today's Range 0.0475 - 0.0535
52wk Range 0.0380 - 0.0767
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Noninvasive Eye Infection Treatment Shows Promise
January 09, 2025
(NewsUSA) - Those who suffer from eye infections that threaten a person’s vision have a new treatment option that is noninvasive and counters the problem of antibiotic resistance, based on recent... 
Via NewsUSA
News headline image
PVCT Stock Earnings: Provectus Reported Results for Q2 2024 ↗
August 13, 2024
Provectus just reported results for the second quarter of 2024. 
Via InvestorPlace

Performance

52-Week Range 30.9% below 52-week high
0.0530
0.0452W Low 0.0852W High
1 Week 0.9% below 1-week high
0.051W Low 0.051W High

Provectus Biopharmaceuticals Inc (PVCT) traded between $0.04 and $0.08 over the past 52 weeks and last traded at $0.05, 30.9% below its 52-week high. Over the past week it ranged between $0.05 and $0.05.

Past 12 Months
+6.4%
N/A
-6.5%
-17.2%
-16.9%
-17.2%
1W +$0.00
1M  
3M -$0.00
6M -$0.01
YTD -$0.01
1Y -$0.01

PVCT was -17.2% over the past year, -17.2% over six months, -16.9% year to date, +6.4% in the last week.

12 Months vs Market
PVCT
-17.2%
DIA
+9.2%
SPY
+9.7%
QQQ
+7.3%
IWM
+13.9%

Over the past 12 months PVCT returned -17.2% versus DIA (Dow) +9.2%, SPY (S&P 500) +9.7%, QQQ (Nasdaq 100) +7.3% and IWM (Russell 2000) +13.9%.

Volume & Liquidity 0.28× 3-mo avg
Today 30,430 3-mo avg 108.7K
1W
76.6K
1M
79.0K
3M
108.7K
6M
137.6K
YTD
204.5K
1Y
218.4K

PVCT most recently traded 30,430 shares against a 3-month average daily volume of 108.7K.

More News

Read More
News headline image
PVCT Stock Earnings: Provectus Reported Results for Q1 2024 ↗
May 14, 2024
Via InvestorPlace
News headline image
PVCT Stock Earnings: Provectus Reported Results for Q4 2023 ↗
March 28, 2024
Via InvestorPlace
News headline image
Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December ↗
January 17, 2023
Via Benzinga
News headline image
Provectus Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek Same Stockholder Approval Again in 2023
December 12, 2022
From Provectus Biopharmaceuticals Inc.
Via GlobeNewswire
News headline image
Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10® and Keytruda® for First-Line Stage III Melanoma at Melanoma Bridge 2022
December 01, 2022
From Provectus Biopharmaceuticals Inc.
Via GlobeNewswire
News headline image
Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022
November 10, 2022
From Provectus Biopharmaceuticals Inc.
Via GlobeNewswire
News headline image
Provectus Biopharmaceuticals Announces World Health Organization Selection of “Rose Bengal Sodium” as International Nonproprietary Name for Active Pharmaceutical Ingredient
November 02, 2022
From Provectus Biopharmaceuticals Inc.
Via GlobeNewswire
News headline image
Provectus Biopharmaceuticals Expands Research Collaboration with The Rockefeller University to Investigate Clinical-Stage Immuno-Dermatology Agent PH-10 for Skin Inflammation
October 25, 2022
From Provectus Biopharmaceuticals Inc.
Via GlobeNewswire
News headline image
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Texas Medical Branch at Galveston to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal for Wound Healing
September 29, 2022
From Provectus Biopharmaceuticals Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Provectus Biopharmaceuticals Inc publicly traded?
Yes, Provectus Biopharmaceuticals Inc is publicly traded.
What exchange does Provectus Biopharmaceuticals Inc trade on?
Provectus Biopharmaceuticals Inc trades on the OTC Traded
What is the ticker symbol for Provectus Biopharmaceuticals Inc?
The ticker symbol for Provectus Biopharmaceuticals Inc is PVCT on the OTC Traded
What is the current price of Provectus Biopharmaceuticals Inc?
The current price of Provectus Biopharmaceuticals Inc is 0.0530
When was Provectus Biopharmaceuticals Inc last traded?
The last trade of Provectus Biopharmaceuticals Inc was at 11/06/26 02:23 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap